NEO - NeoGenomics, Inc.
| Previous Close | 21.79 |
| Open | 21.77 |
| Bid | 21.83 x 4000 |
| Ask | 22.75 x 2200 |
| Day's Range | 21.46 - 22.17 |
| 52 Week Range | 11.05 - 26.89 |
| Volume | 875,043 |
| Avg. Volume | 864,810 |
| Market Cap | 2.268B |
| Beta (3Y Monthly) | 0.57 |
| PE Ratio (TTM) | 1,040.00 |
| EPS (TTM) | 0.02 |
| Earnings Date | Oct 28, 2019 - Nov 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.00 |
- Investor's Business Daily Video
NEO Breaks Out
Cancer testing firm NeoGenomics broke out Thursday from a flat base, a couple of days after reporting strong earnings. NEO is stock of the day. Many cancer-testing firms are doing well.STOCK MARKET TODAY is sponsored by Interactive Brokers. To open an account, go to ibkr.com/whyib
- Simply Wall St.
Introducing NeoGenomics (NASDAQ:NEO), The Stock That Zoomed 298% In The Last Five Years
NeoGenomics, Inc. (NASDAQ:NEO) shareholders have seen the share price descend 14% over the month. But in stark...
- TheStreet.com
NeoGenomics Has Attractive Charts and Should Continue Its Uptrend
During Friday's Lightning Round of Mad Money one caller asked about the Fort Meyers, FL headquartered NeoGenomics : "I won't say no to anyone working to cure cancer," replied Jim Cramer. NeoGenomics is a clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. In this daily bar chart of NEO, below, we can see that prices more than doubled this calendar year.
- ACCESSWIRE
NeoGenomics to Participate in Two Upcoming September Institutional Investor Conferences
The Morgan Stanley conference presentation will be webcast live and accessible online via the investors section of the Company’s website, www.neogenomics.com. NeoGenomics, Inc. specializes in cancer genetic testing and information services.
- Simply Wall St.
We Think NeoGenomics (NASDAQ:NEO) Can Manage Its Debt With Ease
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
- ACCESSWIRE
Neo Performance Materials, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 12, 2019 / Neo Performance Materials, Inc. (NASDAQ: NEO ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 12, 2019 ...
- ACCESSWIRE
NeoGenomics Announces Leadership Transition and Reiterates Recently Increased 2019 Financial Guidance
FT. MYERS, FL / ACCESSWIRE / August 8, 2019 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, this morning filed an 8-K with the Securities and Exchange Commission ...
- Motley Fool
Here's Why Genetic Testing Stocks Rose as Much as 25.4% in July
It was a great month to be a genetic testing company.
- Thomson Reuters StreetEvents
Edited Transcript of NEO earnings conference call or presentation 30-Jul-19 12:30pm GMT
Q2 2019 Neogenomics Inc Earnings Call
- Investor's Business Daily
IBD Stock Of The Day With 93% Gain This Year Breaks Out Again
NeoGenomics stock is the IBD Stock Of The Day as the cancer-testing outlet breaks out on a never-higher relative strength line. Earlier this week, NeoGenomics posted a quarterly beat.
- ACCESSWIRE
NeoGenomics Announces Grand Opening of New Pharma Services Laboratory in Singapore
FORT MYERS, FL and WILMINGTON, NC / ACCESSWIRE / July 31, 2019 / NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetics testing services, and Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), announced the grand opening of a NeoGenomics oncology-focused clinical trials testing lab in the same building as the PPD® Laboratories central lab in Singapore. NeoGenomics’ Pharmaceutical Services Division has established a track record of rapid growth and is building a global network for clinical trials.
Motley FoolNeogenomics Inc (NEO) Q2 2019 Earnings Call Transcript
NEO earnings call for the period ending July 30, 2019.
- Zacks
NeoGenomics (NEO) Meets Q2 Earnings Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and 5.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- ACCESSWIRE
NeoGenomics Reports 50% Revenue Growth to Record $102 Million in the Second Quarter
Second-Quarter Highlights: Consolidated revenue increased 50% to $101.7 million Clinical Services revenue increased 49% to $89.0 million Pharma Services revenue increased 55% to $12.7 million Pharma Services ...
- Zacks
NeoGenomics (NEO) Earnings Expected to Grow: Should You Buy?
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
Here's Why NeoGenomics Stock Rose 74% in the First Half of the Year
The genetic testing leader continues to set new quarterly revenue records.
- Simply Wall St.
NeoGenomics, Inc. (NASDAQ:NEO): Financial Strength Analysis
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as NeoGenomics, Inc...
- ACCESSWIRE
NeoGenomics to Build State-of-the-Art Oncology Laboratory and Global Headquarters in Fort Myers, Florida
MYERS, FL / ACCESSWIRE / July 9, 2019 / NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services, today announced that it intends to build a leading-edge cancer diagnostics testing facility and new global business headquarters in Fort Myers, Florida. Importantly, the site is a short drive from the existing NeoGenomics footprint in Fort Myers and remains in the vicinity of the Southwest Florida International Airport. The Florida Department of Economic Opportunity (“DEO”) and Lee County have agreed to support NeoGenomics’ expansion to encourage the company’s growth of high-paying jobs in a “high-impact sector” of the local economy.
- ACCESSWIRE
NeoGenomics Schedules its Second Quarter Earnings Release for July 30, 2019
FT MYERS, FL / ACCESSWIRE / July 1, 2019 / NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of cancer-focused genetic testing services, announced today that it plans to release its second quarter 2019 ...
- ACCESSWIRE
NeoGenomics Announces New $250 Million Credit Agreement
FORT MYERS, FL / ACCESSWIRE / June 27, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that the company has entered into a new $250 ...
- Insider Monkey
Did Hedge Funds Drop The Ball On NeoGenomics, Inc. (NEO) ?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
- Markit
See what the IHS Markit Score report has to say about Neogenomics Inc.
Neogenomics Inc NASDAQ:NEOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for NEO with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding NEO are favorable, with net inflows of $1.27 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- ACCESSWIRE
NeoGenomics To Present At 39th Annual William Blair Growth Stock Conference
FT. MYERS, FL / ACCESSWIRE / May 30, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chairman and Chief Executive ...
